Array Digital Infrastructure, I (UZD)vsVertex Pharmaceuticals Inc (VRTX)
UZD
Array Digital Infrastructure, I
$18.88
0.00%
NONE · Cap: $2.74B
VRTX
Vertex Pharmaceuticals Inc
$446.83
-0.03%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
UZD
Avoid29
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for UZD.
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 24 in profit
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : UZD
The strongest argument for UZD centers on Return on Equity.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : UZD
The primary concerns for UZD are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
UZD profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor NONE industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (68/100 vs 29/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Array Digital Infrastructure, I
NONE · NONE · USA
United States Cellular Corporation (ticker: UZD) is a leading provider in the U.S. wireless telecommunications sector, offering a wide range of mobile communication services optimized for diverse customer needs across both urban and rural landscapes. Leveraging a resilient network infrastructure, UZD excels in delivering reliable voice, data, and broadband capabilities, with a strong emphasis on technological innovation to improve user experiences and uphold service quality. The company's unwavering focus on customer satisfaction and its strategic investments in emerging technologies position it for sustained growth in a rapidly evolving market, making it an attractive option for institutional investors seeking exposure in the telecommunications arena.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other NONE Stocks
Want to dig deeper into these stocks?